N4 Pharma Past Earnings Performance
Past criteria checks 0/6
N4 Pharma's earnings have been declining at an average annual rate of -0.6%, while the Pharmaceuticals industry saw earnings declining at 5.2% annually. Revenues have been declining at an average rate of 51.2% per year.
Key information
-0.6%
Earnings growth rate
18.4%
EPS growth rate
Pharmaceuticals Industry Growth | 14.1% |
Revenue growth rate | -51.2% |
Return on equity | -87.7% |
Net Margin | -18,399.9% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Companies Like N4 Pharma (LON:N4P) Are In A Position To Invest In Growth
Oct 11Here's Why We're Not Too Worried About N4 Pharma's (LON:N4P) Cash Burn Situation
Jul 06Should Shareholders Have Second Thoughts About A Pay Rise For N4 Pharma Plc's (LON:N4P) CEO This Year?
Mar 18Here's What We Think About N4 Pharma's (LON:N4P) CEO Pay
Mar 01Companies Like N4 Pharma (LON:N4P) Can Afford To Invest In Growth
Dec 07Revenue & Expenses Breakdown
How N4 Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 0 | -1 | 1 | 1 |
31 Mar 24 | 0 | -1 | 1 | 1 |
31 Dec 23 | 0 | -1 | 1 | 1 |
30 Sep 23 | 0 | -1 | 1 | 0 |
30 Jun 23 | 0 | -1 | 1 | 0 |
31 Mar 23 | 0 | -1 | 1 | 0 |
31 Dec 22 | 0 | -1 | 1 | 1 |
30 Sep 22 | 0 | -1 | 1 | 1 |
30 Jun 22 | 0 | -1 | 1 | 1 |
31 Mar 22 | 0 | -1 | 1 | 1 |
31 Dec 21 | 0 | -2 | 1 | 1 |
30 Sep 21 | 0 | -2 | 1 | 1 |
30 Jun 21 | 0 | -2 | 1 | 1 |
31 Mar 21 | 0 | -2 | 1 | 1 |
31 Dec 20 | 0 | -1 | 1 | 1 |
30 Sep 20 | 0 | -1 | 1 | 1 |
30 Jun 20 | 0 | -1 | 1 | 0 |
31 Mar 20 | 0 | -1 | 1 | 0 |
31 Dec 19 | 0 | -1 | 1 | 0 |
30 Sep 19 | 0 | -1 | 1 | 0 |
30 Jun 19 | 0 | -1 | 1 | 1 |
31 Mar 19 | 0 | -1 | 1 | 1 |
31 Dec 18 | 0 | -1 | 1 | 1 |
30 Sep 18 | 0 | -1 | 1 | 1 |
30 Jun 18 | 0 | 0 | 0 | 1 |
31 Mar 18 | 0 | 0 | 0 | 0 |
31 Dec 17 | 0 | -1 | 0 | 0 |
30 Jun 17 | 0 | -2 | 0 | 0 |
31 Mar 17 | 0 | -1 | 0 | 0 |
Quality Earnings: N4P is currently unprofitable.
Growing Profit Margin: N4P is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: N4P is unprofitable, and losses have increased over the past 5 years at a rate of 0.6% per year.
Accelerating Growth: Unable to compare N4P's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: N4P is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.2%).
Return on Equity
High ROE: N4P has a negative Return on Equity (-87.74%), as it is currently unprofitable.